Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
short bowel syndrome
Biotech
Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
James Waldron
Jun 1, 2026 3:52am
Ironwood mulls options after FDA demands further GI drug study
Apr 14, 2025 10:51am
FDA hits Zealand Pharma's Gattex challenger with CRL
Dec 19, 2024 4:22pm
Ironwood makes further bid for $1B GI drug with subgroup data
Oct 28, 2024 12:33pm
Ironwood seeing STARS as phase 3 hit triggers 30% stock drop
Feb 29, 2024 7:52am
Ironwood pays $1B for VectivBio and its phase 3 GI drug
May 22, 2023 10:05am
